Overview

Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize and compare the pharmacokinetics of hPTH(1 34) after treatment with a modified oral formulation (EBP11 and EBP22) versus two dose levels of Entera Bio's extensively studied oral EBP05 1.5 mg and 2.5 mg as well as the commercial Forteo 0.02 mg subcutaneous injection.

Phase:

PHASE1

Details

Lead Sponsor:

Entera Bio Ltd.

Treatments:

Teriparatide